We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Remote Blood Pressure Measurement Helps Monitor Clinical trials

By HospiMedica International staff writers
Posted on 13 Jan 2010
Print article
An innovative blood pressure (BP) telemonitoring and telemedicine device helps health care providers both study and treat patients with chronic heart failure (CHF), diabetes, cancer, and hypertension.

The Tele-monitoring Self Measured Blood Pressure (T-SMBP) device allows for direct capture and remote collection of blood pressure data from a subject's home, and uploading it onto a potential study website. Alert notification can be provided based upon predetermined protocol parameters and ranges. By using the system, a possible reduction in the number of study subjects can be achieved, based on the greater statistical power associated with the use of multiple self-measurement. This offers the potential of evaluating treatment effect within the first two weeks of a study, which is highly predictive of longer-term effects of treatment. Using T-SMBP also contributes to improved patient compliance, resulting in time and cost savings.

Other benefits of implementing T-SMBP include the electronic capture of BP data, which removes transcription errors; a reduction in the number of office visits required by the subject; and real-time access to the subjects' BP data via the study web portal, which allows for an alert criteria process and real-time views of data trends and treatment effects. The T-SMBP system is under development by Medifacts International (Rockville, MD, USA), and is currently undergoing clinical trials.

"We are seeing a very positive reaction to our proactive approach regarding technologies, study designs and timetables. It's important to our clients that we be innovative and driven toward more effective solutions,” said Michael Woehler, president and CEO of Medifacts International. "Our commitment to serve our clients' needs continues to pay dividends as we advance our position as one of the top global companies providing cardiovascular safety solutions.”

Related Links:

Medifacts International



Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Pediatric Bassinet and Trolley
BTC 401
New
AI-Enabled EEG Analysis Software
autoSCORE

Print article

Channels

Critical Care

view channel
Image: The microfluidic chip analyzes the chemotactic migration behaviors of neutrophils in sepsis patients (Talanta, 2024; DOI: 10.1016/j.talanta.2024.126801)

Microfluidic Chip Method to Improve Sepsis Diagnosis, Progression Evaluation and Prognosis Monitoring

Sepsis, a severe and life-threatening condition, results from an uncontrolled immune response that can lead to multi-organ failure. Given its high mortality rate and the limitations of current diagnostic... Read more

Surgical Techniques

view channel
Image: Illustration of how the razor-sharp flakes of graphene line up together on a surface and can kill bacteria without harming healthy human cells (Photo courtesy of Yen Sandqvist)

Ultra-Thin Graphene-Based Coating Material Paves Way for Bacteria-Killing Medical Devices

Healthcare-associated infections are a significant global issue, leading to immense suffering, increased healthcare costs, and a greater risk of antibiotic resistance. These infections often occur when... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Point of Care

view channel
The Atellica VTLi Patient-side Immunoassay Analyzer, a high-sensitivity troponin I test at the bedside, delivers accurate results in just 8 minutes (Photo courtesy of Siemens Healthineers)

New 8-Minute Blood Test to Diagnose or Rule Out Heart Attack Shortens ED Stay

Emergency department overcrowding is a significant global issue that leads to increased mortality and morbidity, with chest pain being one of the most common reasons for hospital admissions.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.